Patents by Inventor Dai Nakae

Dai Nakae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100068746
    Abstract: There is provided an examination method which is simpler than conventional liver biopsy and enables the diagnosis of steatohepatitis. This diagnostic method comprises the steps of measuring the concentration of choline contained in a blood-derived sample collected from a subject; and determining the presence of fatty liver disease, severity of the disease, or a therapeutic effect on the disease based on the choline concentration.
    Type: Application
    Filed: August 31, 2007
    Publication date: March 18, 2010
    Applicant: YOKOHAMA CITY UNIVERSITY
    Inventors: Atsushi Nakajima, Masato Yoneda, Koji Fujita, Dai Nakae, Takeji Takamura, Masakazu Takahashi, Yutaka Hatanaka
  • Patent number: 6569902
    Abstract: PBN (&agr;-phenyl-tert-butylnitrone), and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen species (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development is a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplastic nodule growth in the liver is significantly suppressed by administering PBN, or some of its natural metabolites, in the diet. The effectiveness of PBN in preventing HCC development in the CD liver model is considered due to its prevention of tumor development after the target cells have already been initiated, i.e. genetically changed into tumor cells.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: May 27, 2003
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Robert A. Floyd, Yashige Kotake, Kenneth L. Hensley, Dai Nakae
  • Publication number: 20020004531
    Abstract: PBN (&agr;-phenyl-tert-butylnitrone), and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen species (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development is a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplastic nodule growth in the liver is significantly suppressed by administering PBN, or some ofits natural metabolites, in the diet. The effectiveness of PBN in preventing HCC development in the CD liver model is considered due to its prevention of tumor development after the target cells have already been initiated, i.e.genetically changed into tumor cells.
    Type: Application
    Filed: March 28, 2001
    Publication date: January 10, 2002
    Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Robert A. Floyd, Yashige Kotake, Kenneth L. Hensley, Dai Nakae